Want to see SONX full AI Analyst Report?
Top Page
Sonendo
(OTC:SONX)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.53
▼(-48.02% Downside)
Action:Reiterated
Date:08/17/26
The score is primarily constrained by weak financial quality—continued losses and negative cash flow alongside negative stockholders’ equity—despite improvement in loss and cash-burn trends. Technicals also detract as the stock trades below key moving averages with very weak RSI. Valuation provides little offset due to negative earnings and no dividend yield data.
Positive Factors
Improving Loss Profile
The substantial reduction in net losses indicates meaningful cost control and/or mix improvement. If maintained, this trend could extend the company’s funding runway and improve its path toward sustainable profitability, despite earnings remaining negative.
Negative Factors
Revenue Contraction
Two consecutive years of declining revenue raise concerns about product adoption, procedure volumes, or sales execution in a medical-device business. Persistent contraction could limit operating leverage and make it harder for recent cost improvements to translate into durable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Loss Profile
The substantial reduction in net losses indicates meaningful cost control and/or mix improvement. If maintained, this trend could extend the company’s funding runway and improve its path toward sustainable profitability, despite earnings remaining negative.
Read all positive factors
Sonendo (SONX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$235.07K
Dividend YieldN/A
Average Volume (3M)389.00
Price to Earnings (P/E)―
Beta (1Y)-1.29
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees130
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.36
Shares Outstanding427,401
10 Day Avg. Volume222
30 Day Avg. Volume389
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.62
Price to Sales (P/S)0.05
P/FCF Ratio-0.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-46.56
Revenue Forecast (FY)$42.30M
Sonendo Business Overview & Revenue Model
Company Description
Sonendo, Inc. operates as a commercial-stage medical technology firm, dedicated to innovating, producing, and marketing advanced devices for root canal treatment across the United States and Canada. A flagship offering is GentleWave, an innovative...
How the Company Makes Money
Sonendo makes money primarily by selling (1) capital equipment and (2) recurring procedure-related consumables associated with the GentleWave System. The capital equipment stream comes from the sale of the GentleWave console/system placed in denta...
Sonendo Earnings Call Summary
Earnings Call Date:Aug 07, 2024
(Q2-2024)
| % Change Since: |
Next Earnings Date:Mar 23, 2027
Earnings Call Sentiment Positive
The earnings call for Sonendo reflects a positive sentiment overall, with significant improvements in gross margins, operating expenses, and adjusted EBITDA loss, despite challenges in PI sales and total revenue decline. The company is optimistic about its strategic reset and future growth prospects.Positive Updates
Strong Growth in Console Sales
Sonendo experienced a 7% year-over-year growth in console sales, selling more consoles compared to the second quarter of 2023, and maintaining a healthy unit backlog.
Negative Updates
Decrease in PI Revenue
PI revenue for Q2 2024 totaled $4.7 million, down from $5.6 million in Q2 2023, with the decline primarily volume-related.
Read all updates
Q2-2024 Updates
Positive
Negative
Strong Growth in Console Sales
Sonendo experienced a 7% year-over-year growth in console sales, selling more consoles compared to the second quarter of 2023, and maintaining a healthy unit backlog.
Read all positive updates
Company Guidance
During the Sonendo Q2 2024 earnings call, the company provided updated guidance and highlighted several key metrics illustrating their progress. Sonendo raised their full-year 2024 revenue guidance to a range of $31 million to $32 million, up from the previous $29 million to $31 million. They reported a significant improvement in gross margins, with adjusted gross margin increasing to 40.7% in Q2 2024 from 28.7% in the prior year quarter. The company also achieved a 53% reduction in year-over-year adjusted EBITDA loss, reporting a loss of $5.7 million for the quarter. Sonendo's strategic reset focused on commercial execution, gross margin expansion, and cash conservation, with a notable 42% reduction in operating expenses compared to the prior year. Despite a decrease in PI sales by 15% year-over-year, the company emphasized stabilizing utilization rates and anticipates low single-digit growth in PI sales for the second half of the year. Additionally, Sonendo aims to achieve adjusted gross margins in the 40% to 41% range for the latter half of 2024, with long-term aspirations of reaching 60% as they continue to enhance their operational and financial performance.Sonendo Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
18
Very Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 31.70M | 28.55M | 31.70M | 43.87M | 41.66M | 33.20M |
| Gross Profit | 11.84M | 11.97M | 11.84M | 10.72M | 10.48M | 8.34M |
| EBITDA | -27.69M | -12.62M | -26.61M | -54.77M | -51.00M | -41.29M |
| Net Income | -28.03M | -14.41M | -28.03M | -60.92M | -57.05M | -48.50M |
Balance Sheet | ||||||
| Total Assets | 31.27M | 18.84M | 31.27M | 78.16M | 137.28M | 115.50M |
| Cash, Cash Equivalents and Short-Term Investments | 11.63M | 5.01M | 11.63M | 46.78M | 91.45M | 84.64M |
| Total Debt | 18.93M | 16.16M | 18.93M | 40.35M | 38.95M | 29.20M |
| Total Liabilities | 26.07M | 21.15M | 26.07M | 49.74M | 55.33M | 43.44M |
| Stockholders Equity | 5.19M | -2.32M | 5.19M | 28.42M | 81.95M | 72.06M |
Cash Flow | ||||||
| Free Cash Flow | -24.81M | -11.02M | -24.81M | -46.99M | -62.43M | -50.58M |
| Operating Cash Flow | -24.65M | -11.02M | -24.65M | -46.06M | -61.07M | -48.60M |
| Investing Cash Flow | 45.81M | 2.40M | 45.81M | 42.40M | -74.43M | -1.97M |
| Financing Cash Flow | -24.95M | 3.41M | -24.95M | 4.00K | 68.53M | 83.50M |
Sonendo Technical Analysis
Negative
1.01
Price Trends
0.75
Negative
0.61
Negative
0.40
Positive
Market Momentum
0.03
Positive
19.20
Positive
44.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SONX, the sentiment is Negative. The current price of 1.01 is above the 20-day moving average (MA) of 0.95, above the 50-day MA of 0.75, and above the 200-day MA of 0.40, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 19.20 is Positive, neither overbought nor oversold. The STOCH value of 44.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SONX.
Sonendo Risk Analysis
Sonendo disclosed 85 risk factors in its most recent earnings report. Sonendo reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sonendo Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $21.07M | -0.44 | -243.14% | ― | -10.68% | 55.33% | |
46 Neutral | $89.89M | -5.86 | 524.69% | ― | 33.45% | 0.24% | |
44 Neutral | $323.89M | -0.96 | -9.69% | ― | 843.62% | 21.98% | |
43 Neutral | $37.23M | -0.32 | -33.51% | ― | -89.02% | -107.75% | |
43 Neutral | $61.76M | -1.19 | 1719.71% | ― | -6.76% | 42.70% | |
41 Neutral | $235.07K | -0.18 | -199.60% | ― | ― | ― |
* Healthcare Sector Average
SONX
Sonendo
0.55
0.52
1733.33%
LFWD
Lifeward
7.45
-0.21
-2.80%
ECOR
Electrocore
9.97
4.61
85.83%
PAVM
PAVmed
5.20
-7.74
-59.81%
MOVE
Movano
11.72
7.18
158.38%
COCH
Envoy Medical
0.80
-0.55
-40.74%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.